KLRS
Kalaris Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.02
−1.46%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.10
From 52W high−81.60%
Volume28255.00
Market cap$48.09M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.10
From 52W high
−81.60%
Volume
28255.00
Market cap
$48.09M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.0x
P/E (TTM)
—
RSI (14)
39.8
MomentumView details →
1D Return
−1.46%
YTD Return
−75.41%
SummaryUpdated Jun 1, 2026
Kalaris Therapeutics Inc (NASDAQ:KLRS) is a pharmaceutical company founded in 2020 that specializes in developing novel cell therapies for patients with severely compromised immune systems. The company went public on July 30, 2020, and focuses specifically on creating treatments to restore natural immunity against life-threatening virus-associated diseases. As a clinical-stage biotechnology company, Kalaris operates in the specialized field of immunotherapy, targeting patients whose immune systems have been weakened by conditions such as cancer treatments, organ transplants, or other medical interventions.
Similar companies
Latest newsMore news →
Kalaris Therapeutics, Inc. reported a net loss of $11.5 million for Q2 2026, with diluted loss per share of $0.48, and held $93.5 million in cash, cash equivalents, and marketable securities as of June 30, 2026.86d agoKalaris Therapeutics Inc.'s stock price rose 15.4% during mid-day trading on Monday, trading as high as $4.09 and last at $4.05, with volume of 155,903 shares.93d ago